Can AI identify early-stage lung cancer from breath biomarkers using portable electronic noses ?

Certain volatile organic compounds in exhaled breath change in presence of early lung cancer, even before imaging detects tumors. AI-powered electronic noses could analyze breath samples in clinics or pharmacies. This could reduce reliance on invasive biopsies and CT scans. However, environmental factors like smoking or air pollution may confound results.

Researchers have demonstrated that portable electronic noses (e-noses) can detect volatile organic compounds (VOCs) in exhaled breath with promising sensitivity and specificity for early-stage lung cancer screening. A 2022 meta-analysis reported pooled sensitivity of about 85% and specificity of 87% across multiple studies using machine-learning models trained on breath-chemistry data. However, real-world deployment faces challenges such as sensor drift, environmental confounders like smoking or diet, and the need for larger, multi-center validation cohorts. Regulatory approval remains limited to a few devices with narrow indications, underscoring the gap between promising research and routine clinical use.

— Enriched May 12, 2026 · Source: European Respiratory Journal